Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Practice: Mini-Review

Free Access

Care of the Acute Kidney Injury Survivor

Wald R.a · Kitchlu A.a · Harel Z.a · Silver S.A.b

Author affiliations

aDivision of Nephrology, St. Michael’s Hospital and University of Toronto, Toronto, ON, Canada
bDivision of Nephrology, Queen’s University, Kingston, ON, Canada

Corresponding Author

Dr. Ron Wald

Division of Nephrology, St. Michael’s Hospital

61 Queen Street East

9-140 Toronto, ON M5C 2T2 (Canada)

E-Mail waldr@smh.ca

Related Articles for ""

Nephron 2017;137:306–309

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

While the short-term implications of acute kidney injury (AKI) have been known for many years, far less attention has been paid to the health of AKI survivors. This was perhaps fueled by a prevailing wisdom that if a patient was fortunate enough to survive the primary illness associated with AKI, the prognosis for future health was auspicious. More recently, this dogma was challenged by data suggesting that after an episode of AKI, patients remain at risk of experiencing multiple adverse health outcomes. Greater recognition and appreciation of the risks faced by AKI survivors have led to the development of quality improvement initiatives that are supposed to enrich this vulnerable population.

© 2017 S. Karger AG, Basel


References

  1. Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill SL, Hoste E, Koyner J, Liu KD, Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, Palevsky PM, Pannu N, Rosner M, Wald R, Zarbock A, Ronco C, Kellum JA; Acute Disease Quality Initiative Workgroup 16: Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 2017; 13: 241–257.
  2. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG; University of Toronto Acute Kidney Injury Research Group: Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009; 302: 1179–1185.
  3. Wald R, Quinn RR, Adhikari NK, Burns KE, Friedrich JO, Garg AX, Harel Z, Hladunewich MA, Luo J, Mamdani M, Perl J, Ray JG; University of Toronto Acute Kidney Injury Research Group: Risk of chronic dialysis and death following acute kidney injury. Am J Med 2012; 125: 585–593.
  4. Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE 2nd, Perkins RM: Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 2012; 81: 477–485.
  5. Siew ED, Peterson JF, Eden SK, Hung AM, Speroff T, Ikizler TA, Matheny ME: Outpatient nephrology referral rates after acute kidney injury. J Am Soc Nephrol 2012; 23: 305–312.
  6. Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL: Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol 2014; 9: 448–456.
  7. Hsu CY, Hsu RK, Yang J, Ordonez JD, Zheng S, Go AS: Elevated BP after AKI. J Am Soc Nephrol 2016; 27: 914–923.
  8. Wu VC, Wu CH, Huang TM, Wang CY, Lai CF, Shiao CC, Chang CH, Lin SL, Chen YY, Chen YM, Chu TS, Chiang WC, Wu KD, Tsai PR, Chen L, Ko WJ; NSARF Group: Long-term risk of coronary events after AKI. J Am Soc Nephrol 2014; 25: 595–605.
  9. Wu VC, Wu PC, Wu CH, Huang TM, Chang CH, Tsai PR, Ko WJ, Chen L, Wang CY, Chu TS, Wu KD; National Taiwan University Study Group on Acute Renal Failure (NSARF) Group: The impact of acute kidney injury on the long-term risk of stroke. J Am Heart Assoc 2014; 3:pii:e000933.
  10. Gammelager H, Christiansen CF, Johansen MB, Tønnesen E, Jespersen B, Sørensen HT: Three-year risk of cardiovascular disease among intensive care patients with acute kidney injury: a population-based cohort study. Crit Care 2014; 18: 492.
  11. Odutayo A, Wong CX, Farkouh M, Altman DG, Hopewell S, Emdin CA, Hunn BH: AKI and long-term risk for cardiovascular events and mortality. J Am Soc Nephrol 2017; 28: 377–387.
  12. Silver SA, Long J, Zheng Y, Chertow GM: Cost of acute kidney injury in hospitalized patients. J Hosp Med 2017; 12: 70–76.
  13. Silver SA, Harel Z, McArthur E, Nash DM, Acedillo R, Kitchlu A, Garg AX, Chertow GM, Bell CM, Wald R: 30-Day readmissions after an acute kidney injury hospitalization. Am J Med 2017; 130: 163–172.e164.
  14. Siew ED, Parr SK, Abdel-Kader K, Eden SK, Peterson JF, Bansal N, Hung AM, Fly J, Speroff T, Ikizler TA, Matheny ME: Predictors of recurrent AKI. J Am Soc Nephrol 2016; 27: 1190–1200.
  15. Johansen KL, Smith MW, Unruh ML, Siroka AM, O’Connor TZ, Palevsky PM; VA/NIH Acute Renal Failure Trial Network: Predictors of health utility among 60-day survivors of acute kidney injury in the veterans affairs/national institutes of health acute renal failure trial network study. Clin J Am Soc Nephrol 2010; 5: 1366–1372.
  16. Joyce VR, Smith MW, Johansen KL, Unruh ML, Siroka AM, O’Connor TZ, Palevsky PM; Veteran Affairs/National Institutes of Health Acute Renal Failure Trial Network: Health-related quality of life as a predictor of mortality among survivors of AKI. Clin J Am Soc Nephrol 2012; 7: 1063–1070.
  17. Vaara ST, Pettila V, Reinikainen M, Kaukonen KM; Finnish Intensive Care C: Population-based incidence, mortality and quality of life in critically ill patients treated with renal replacement therapy: a nationwide retrospective cohort study in Finnish intensive care units. Crit Care 2012; 16: R13.
  18. Oeyen S, De Corte W, Benoit D, Annemans L, Dhondt A, Vanholder R, Decruyenaere J, Hoste E: Long-term quality of life in critically ill patients with acute kidney injury treated with renal replacement therapy: a matched cohort study. Crit Care 2015; 19: 289.
  19. KDIGO: clinical practice guideline for acute kidney injury. Kidney Int 2012; 2(suppl 1):1–138.
  20. Matheny ME, Peterson JF, Eden SK, Hung AM, Speroff T, Abdel-Kader K, Parr SK, Ikizler TA, Siew ED: Laboratory test surveillance following acute kidney injury. PLoS One 2014; 9:e103746.
  21. Harel Z, Wald R, Bargman JM, Mamdani M, Etchells E, Garg AX, Ray JG, Luo J, Li P, Quinn RR, Forster A, Perl J, Bell CM: Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. Kidney Int 2013; 83: 901–908.
  22. Silver SA, Goldstein SL, Harel Z, Harvey A, Rompies EJ, Adhikari NK, Acedillo R, Jain AK, Richardson R, Chan CT, Chertow GM, Bell CM, Wald R: Ambulatory care after acute kidney injury: an opportunity to improve patient outcomes. Can J Kidney Health Dis 2015; 2: 36.

Article / Publication Details

First-Page Preview
Abstract of Clinical Practice: Mini-Review

Received: June 02, 2017
Accepted: October 05, 2017
Published online: November 13, 2017
Issue release date: Published online first

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.